After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Gilead Sciences (GILD) is a stock that can certainly grab the ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Incyte INCY announced positive results from two late-stage studies evaluating the safety and efficacy of its twice-daily ...

Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...

Weeks after settling a five-year patent dispute with the U.S. | Gilead set aside approximately $200 million for a potential ...

Gilead Sciences (NASDAQ:GILD – Get Free Report) had its target price upped by Wells Fargo & Company from $120.00 to $140.00 ...

Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term ...

Gilead Sciences (NASDAQ:GILD – Free Report) had its price target raised by Oppenheimer from $115.00 to $132.00 in a report ...

The board of Gilead Sciences, Inc. ( NASDAQ:GILD ) has announced that it will be paying its dividend of $0.79 on ...

Gilead Sciences, Inc.'s ( NASDAQ:GILD ) recent soft profit numbers didn't appear to worry shareholders, as the ...

Co-founder Finny Kuruvilla manages the firm’s largest two funds — Eventide Gilead and Eventide Healthcare and Life Sciences — and remains the firm’s largest owner, though more than 20 of ...